[68Ga]Ga-DOTA-Exendin-4 PET/CT for the localisation of insulinoma: Results of an international, dual-centre, retrospective, open-label real-world imaging study

#4623

Introduction: Benign insulinomas are the main cause of endogenous hyperinsulinemic hypoglycaemia (EHH) in adults, with surgery as the only cure. Pancreas-preserving procedures are preferred, making precise localisation crucial. Recent studies indicate that GLP-1R imaging, such as [68Ga]Ga-DOTA-exendin-4 (68Ga-Ex4) PET/CT, outperforms conventional imaging in identifying insulinomas.

Aim(s): The goal of this study was to generate real-life data for the detection rate of insulinoma with 68Ga-Ex4 PET/CT in patients with negative/inconclusive workup on prior conventional imaging.

Materials and methods: In this retrospective, real-life, dual-centre imaging study, patients with biochemically proven EHH and/or a positive Whipple triad underwent 68Ga-Ex4 PET/CT at two tertiary centres between April 2017 and March 2024. Endpoints: 68Ga-Ex4 PET/CT detection rate after inconclusive conventional workup (gold standard: histology) and impact on patient management.

Conference:

Presenting Author: Fricke J

Authors: Fricke J, Laubner K, Schildmeijer M, Menz L, Christ E,

Keywords: GLP1-Receptor PET/CT, Insulinoma, nesidioblatosis, endogenous hyperinsulinemic hypoglycaemia, real-life data,